This review summarizes the mechanisms of action and clinical activity of IMiDs in MM. Multiple myeloma (MM) is a malignant plasma cell disorder accounting for approximately 10% of all hematologic ...

Minimal residual disease (MRD) has emerged as a significant marker in the treatment of multiple myeloma (MM), allowing ...

Matias Sanchez, MD, assistant professor in the Department of Medicine at the University of Illinois Chicago, discussed recent advancements in multiple myeloma treatment, including the potential of ...

Despite challenges such as high attrition rates and adverse events, the trial highlights the value of established therapies ...

A ground breaking study mapping the immune microenvironment in Multiple Myeloma identifies critical immune changes and ...

The data of 76 patients with 190 kyphoplasty-treated vertebrae were analyzed retrospectively (Figure 3). In our collective, the standard postoperative CT of the kyphoplasty-treated vertebrae ...

International Myeloma Foundation: “Multiple Myeloma and Anemia,” “Heart and Lung Complications.” Memorial Sloan Kettering Cancer Center: “Bone-Related Problems in Multiple Myeloma ...

To investigate whether this had actually happened, two studies were conducted, including 54 patients with monoclonal ...

A stem cell transplant can be a good treatment for multiple myeloma. A successful transplant gives someone with multiple myeloma new, healthy bone marrow. It replaces the bone marrow harmed by myeloma ...

Multiple myeloma is a rare type of cancer. It starts with the uncontrolled production of plasma cells. These are a type of white blood cell in the bone marrow. Healthy plasma cells make antibodies ...

New Endowed Professorship in Cancer Pathobiology: The Department of Pathology is pleased to announce the appointment ... sulfate proteoglycans promote tumor growth and metastasis of multiple myeloma ...

Dr Martin Kaiser’s group aims to design gentler, tailored therapies for patients with multiple myeloma, an immune cell cancer of the bone marrow. I joined the team in December 2020 and I am involved ...